Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for INDV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 221.58M
March 31, 2026 -29.00M
December 31, 2025 -249.85M
September 30, 2025 -62.24M
June 30, 2025 147.23M
March 31, 2025 70.00M
December 31, 2024 -33.68M
September 30, 2024 -4.199M
June 30, 2024 82.90M
March 31, 2024 -40.00M
December 31, 2023 -298.31M
September 30, 2023 -6.725M
June 30, 2023 -19.67M
March 31, 2023 -42.00M
December 31, 2022 -18.83M
September 30, 2022 54.67M
June 30, 2022 21.77M
March 31, 2022 -75.00M
December 31, 2021 162.27M
September 30, 2021 25.71M
June 30, 2021 39.64M
March 31, 2021 89.00M
December 31, 2020 -74.32M
Date Value
September 30, 2020 26.08M
June 30, 2020 -4.046M
March 31, 2020 -146.00M
December 31, 2019 35.95M
September 30, 2019 37.99M
June 30, 2019 -61.71M
March 31, 2019 133.00M
December 31, 2018 83.03M
September 30, 2018 100.87M
June 30, 2018 56.56M
March 31, 2018 18.00M
December 31, 2017 56.33M
September 30, 2017 24.90M
June 30, 2017 118.08M
March 31, 2017 52.00M
December 31, 2016 129.00M
September 30, 2016 101.42M
June 30, 2016 76.75M
March 31, 2016 93.00M
December 31, 2015 36.32M
September 30, 2015 47.80M
June 30, 2015 40.95M
March 31, 2015 165.00M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Supernus Pharmaceuticals, Inc. -5.378M
Liquidia Corp. 69.01M
Corcept Therapeutics, Inc. 31.02M
Prestige Consumer Healthcare, Inc. 67.08M
Harrow, Inc. -28.29M